The relative efficacy of imatinib, dasatinib and nilotinib for newly diagnosed chronic myeloid leukemia: a systematic review and network meta-analysis

OBJECTIVES: Dasatinib 100 mg daily and nilotinib 600/800 mg daily have been compared to imatinib as first line treatments for CML in two recent randomised studies. However, no head to head evidence exists of the relative efficacy of dasatinib and nilotinib. METHODS: We conducted a systematic literat...

Descripción completa

Detalles Bibliográficos
Autores principales: Mealing, Stuart, Barcena, Leticia, Hawkins, Neil, Clark, James, Eaton, Victoria, Hirji, Ishan, Davis, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585848/
https://www.ncbi.nlm.nih.gov/pubmed/23422286
http://dx.doi.org/10.1186/2162-3619-2-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585848/
https://www.ncbi.nlm.nih.gov/pubmed/23422286
http://dx.doi.org/10.1186/2162-3619-2-5

Ejemplares similares